Medidata
As the industry is coming to know, risk-based monitoring can significantly reduce study monitoring costs through the promise of reducing on-site visits. Over the past few years, there has been a downward trend in the number of visit days per year, per site across the clinical trial landscape, as supported by data pulled from the Medidata InsightsTM metrics warehouse (Figure 1).
Based on this trend, some might assume there would also be a similar reduction in the query open rate of site monitors coupled with a corresponding uptick in the number of data manager queries—indicating possible “compensation” for mistakes/inconsistencies not captured by monitors.
However, based on the analysis depicted in Figure 1, the number of site monitor and data manager queries has remained relatively flat since 2010. Conversely, there was an increase in the rate of auto queries—those generated programmatically by the electronic data capture (EDC) system in response to electronic case report form (eCRF) data entries that violate rules/boundary conditions. Auto queries are generated at the time of data entry and flag many of the data errors that would otherwise be manually detected by site monitors or data managers. Since the per-query cost for auto queries is significantly lower than that for manual queries, using edit check/auto query technology delivers a more attractive return on investment (ROI) than manual queries. Further, the analysis revealed a 16% increase in the frequency of auto queries over the three-year period that inversely corresponds to a 28% decrease in the site visit rate.
Based on this analysis of the data, we conclude that the higher rate of auto queries is not specifically related to the decrease in on-site monitoring, but rather a result of increased adoption of the edit checking technology inherent in most EDC systems. This is a positive sign that the industry is maturing in its use of EDC and realizing the tremendous value this capability offers toward ensuring data quality. The results may also indicate that site monitors are becoming more efficient since their query rates remain level for both on- and off-site queries, even though they’re spending fewer days at sites year after year. So even though sites may not be seeing their site monitors as frequently, they can rest assured knowing their query rate remains the same!
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.